834 related articles for article (PubMed ID: 29356032)
21. Liver fat quantification: where do we stand?
Starekova J; Reeder SB
Abdom Radiol (NY); 2020 Nov; 45(11):3386-3399. PubMed ID: 33025153
[TBL] [Abstract][Full Text] [Related]
22. Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH.
Loomba R; Neuschwander-Tetri BA; Sanyal A; Chalasani N; Diehl AM; Terrault N; Kowdley K; Dasarathy S; Kleiner D; Behling C; Lavine J; Van Natta M; Middleton M; Tonascia J; Sirlin C;
Hepatology; 2020 Oct; 72(4):1219-1229. PubMed ID: 31965579
[TBL] [Abstract][Full Text] [Related]
23. Noninvasive monitoring of hepatic steatosis: controlled attenuation parameter and magnetic resonance imaging-proton density fat fraction in patients with nonalcoholic fatty liver disease.
Lee SJ; Kim SU
Expert Rev Gastroenterol Hepatol; 2019 Jun; 13(6):523-530. PubMed ID: 31018719
[TBL] [Abstract][Full Text] [Related]
24. Hepatic R2* is more strongly associated with proton density fat fraction than histologic liver iron scores in patients with nonalcoholic fatty liver disease.
Bashir MR; Wolfson T; Gamst AC; Fowler KJ; Ohliger M; Shah SN; Alazraki A; Trout AT; Behling C; Allende DS; Loomba R; Sanyal A; Schwimmer J; Lavine JE; Shen W; Tonascia J; Van Natta ML; Mamidipalli A; Hooker J; Kowdley KV; Middleton MS; Sirlin CB;
J Magn Reson Imaging; 2019 May; 49(5):1456-1466. PubMed ID: 30318834
[TBL] [Abstract][Full Text] [Related]
25. Noninvasive Diagnosis of NAFLD and NASH.
Piazzolla VA; Mangia A
Cells; 2020 Apr; 9(4):. PubMed ID: 32316690
[TBL] [Abstract][Full Text] [Related]
26. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD.
Tamaki N; Ajmera V; Loomba R
Nat Rev Endocrinol; 2022 Jan; 18(1):55-66. PubMed ID: 34815553
[TBL] [Abstract][Full Text] [Related]
27. Automated Analysis of Multiparametric Magnetic Resonance Imaging/Magnetic Resonance Elastography Exams for Prediction of Nonalcoholic Steatohepatitis.
Dzyubak B; Li J; Chen J; Mara KC; Therneau TM; Venkatesh SK; Ehman RL; Allen AM; Yin M
J Magn Reson Imaging; 2021 Jul; 54(1):122-131. PubMed ID: 33586159
[TBL] [Abstract][Full Text] [Related]
28. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.
Tsai E; Lee TP
Clin Liver Dis; 2018 Feb; 22(1):73-92. PubMed ID: 29128062
[TBL] [Abstract][Full Text] [Related]
29. Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS): Assessment & validation of imaging modality performance across the NAFLD spectrum in a prospectively recruited cohort study (the LITMUS imaging study): Study protocol.
Pavlides M; Mózes FE; Akhtar S; Wonders K; Cobbold J; Tunnicliffe EM; Allison M; Godfrey EM; Aithal GP; Francis S; Romero-Gomez M; Castell J; Fernandez-Lizaranzu I; Aller R; González RS; Agustin S; Pericàs JM; Boursier J; Aube C; Ratziu V; Wagner M; Petta S; Antonucci M; Bugianesi E; Faletti R; Miele L; Geier A; Schattenberg JM; Tilman E; Ekstedt M; Lundberg P; Berzigotti A; Huber AT; Papatheodoridis G; Yki-Järvinen H; Porthan K; Schneider MJ; Hockings P; Shumbayawonda E; Banerjee R; Pepin K; Kalutkiewicz M; Ehman RL; Trylesinksi A; Coxson HO; ; Martic M; Yunis C; Tuthill T; Bossuyt PM; Anstee QM; Neubauer S; Harrison S
Contemp Clin Trials; 2023 Nov; 134():107352. PubMed ID: 37802221
[TBL] [Abstract][Full Text] [Related]
30. Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD).
Han MA; Saouaf R; Ayoub W; Todo T; Mena E; Noureddin M
Expert Rev Clin Pharmacol; 2017 Apr; 10(4):379-390. PubMed ID: 28277807
[TBL] [Abstract][Full Text] [Related]
31. Hepatic Alanine Differentiates Nonalcoholic Steatohepatitis From Simple Steatosis in Humans and Mice: A Proton MR Spectroscopy Study With Long Echo Time.
Kim TH; Jun HY; Kim KJ; Lee YH; Lee MS; Choi KH; Yun KJ; Jeong YY; Jun CH; Cho EY; Yoon KH
J Magn Reson Imaging; 2017 Nov; 46(5):1298-1310. PubMed ID: 28225569
[TBL] [Abstract][Full Text] [Related]
32. The Role of Three-Dimensional Magnetic Resonance Elastography in the Diagnosis of Nonalcoholic Steatohepatitis in Obese Patients Undergoing Bariatric Surgery.
Allen AM; Shah VH; Therneau TM; Venkatesh SK; Mounajjed T; Larson JJ; Mara KC; Schulte PJ; Kellogg TA; Kendrick ML; McKenzie TJ; Greiner SM; Li J; Glaser KJ; Wells ML; Chen J; Ehman RL; Yin M
Hepatology; 2020 Feb; 71(2):510-521. PubMed ID: 30582669
[TBL] [Abstract][Full Text] [Related]
33. Nonalcoholic Steatohepatitis: A Review.
Sheka AC; Adeyi O; Thompson J; Hameed B; Crawford PA; Ikramuddin S
JAMA; 2020 Mar; 323(12):1175-1183. PubMed ID: 32207804
[TBL] [Abstract][Full Text] [Related]
34. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Harrison SA; Bashir MR; Guy CD; Zhou R; Moylan CA; Frias JP; Alkhouri N; Bansal MB; Baum S; Neuschwander-Tetri BA; Taub R; Moussa SE
Lancet; 2019 Nov; 394(10213):2012-2024. PubMed ID: 31727409
[TBL] [Abstract][Full Text] [Related]
35. Assessment of treatment response in non-alcoholic steatohepatitis using advanced magnetic resonance imaging.
Lin SC; Heba E; Bettencourt R; Lin GY; Valasek MA; Lunde O; Hamilton G; Sirlin CB; Loomba R
Aliment Pharmacol Ther; 2017 Mar; 45(6):844-854. PubMed ID: 28116801
[TBL] [Abstract][Full Text] [Related]
36. Noninvasive Diagnosis of Nonalcoholic Fatty Liver Disease and Quantification of Liver Fat Using a New Quantitative Ultrasound Technique.
Lin SC; Heba E; Wolfson T; Ang B; Gamst A; Han A; Erdman JW; O'Brien WD; Andre MP; Sirlin CB; Loomba R
Clin Gastroenterol Hepatol; 2015 Jul; 13(7):1337-1345.e6. PubMed ID: 25478922
[TBL] [Abstract][Full Text] [Related]
37. Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease.
Tamaki N; Munaganuru N; Jung J; Yonan AQ; Loomba RR; Bettencourt R; Ajmera V; Valasek MA; Behling C; Sirlin CB; Loomba R
Gut; 2022 May; 71(5):983-990. PubMed ID: 33883248
[TBL] [Abstract][Full Text] [Related]
38. Liver Iron Load Influences Hepatic Fat Fraction in End-Stage Renal Disease Patients on Dialysis: A Proof of Concept Study.
Rostoker G; Loridon C; Griuncelli M; Rabaté C; Lepeytre F; Ureña-Torres P; Issad B; Ghali N; Cohen Y
EBioMedicine; 2019 Jan; 39():461-471. PubMed ID: 30502056
[TBL] [Abstract][Full Text] [Related]
39. Accuracy of multi-echo Dixon sequence in quantification of hepatic steatosis in Chinese children and adolescents.
Zhao YZ; Gan YG; Zhou JL; Liu JQ; Cao WG; Cheng SM; Bai DM; Wang MZ; Gao FQ; Zhou SM
World J Gastroenterol; 2019 Mar; 25(12):1513-1523. PubMed ID: 30948914
[TBL] [Abstract][Full Text] [Related]
40. Effect of 12-week intermittent calorie restriction compared to standard of care in patients with nonalcoholic fatty liver disease: a randomized controlled trial.
Lee HA; Moon H; Kim Y; Lee HA; Kim HY
Trials; 2023 Aug; 24(1):490. PubMed ID: 37533096
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
